161 related articles for article (PubMed ID: 3032612)
1. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
Jorgensen JH; Maher LA; Redding JS
Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of LY146032 (daptomycin), a new peptolide.
Ehlert F; Neu HC
Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
Machka K; Braveny I
Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
[TBL] [Abstract][Full Text] [Related]
5. LY146032: activity and resistance development in vitro.
Mouton RP; Mulders SL
J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of LY264826 compared to other glycopeptides and daptomycin.
Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(2):181-4. PubMed ID: 1651826
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the new glycopeptide decaplanin.
Neu HC; Chin NX; Niu WW
Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
Van der Auwera P; Grenier P; Klastersky J
J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
[TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
Coudron PE; Johnston JL; Archer GL
J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
[TBL] [Abstract][Full Text] [Related]
11. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
Benson CA; Beaudette F; Trenholm G
J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
[TBL] [Abstract][Full Text] [Related]
12. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
Jones RN; Barry AL
Antimicrob Agents Chemother; 1987 Apr; 31(4):625-9. PubMed ID: 3038001
[TBL] [Abstract][Full Text] [Related]
14. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
King A; Phillips I
J Antimicrob Chemother; 2001 Aug; 48(2):219-23. PubMed ID: 11481291
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.
Fass RJ; Helsel VL
Antimicrob Agents Chemother; 1986 Nov; 30(5):781-4. PubMed ID: 3026240
[TBL] [Abstract][Full Text] [Related]
17. In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide.
Liebowitz LD; Saunders J; Chalkley LJ; Koornhof HJ
Antimicrob Agents Chemother; 1988 Jan; 32(1):24-6. PubMed ID: 2831813
[TBL] [Abstract][Full Text] [Related]
18. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
Pohlod DJ; Saravolatz LD; Somerville MM
J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
[TBL] [Abstract][Full Text] [Related]
19. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
Stratton CW; Liu C; Weeks LS
Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
Verbist L
Antimicrob Agents Chemother; 1987 Feb; 31(2):340-2. PubMed ID: 3032099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
